LiCl and SB216763 had no significant effect on cell apoptosis in

LiCl and SB216763 had no significant effect on cell apoptosis in normal BMMC. Columns, mean; bars, SD. *P < 0.05, **P < 0.01 vs. control. All assays

were performed in triplicate. GSK-3β inhibitors had no significant effect on cell apoptosis in normal BMMC To further evaluate whether GSK-3β inhibition Evofosfamide manufacturer specifically induced apoptosis in ALL cells, we examined the effect of GSK-3β inhibitors on normal BMMC. GSK-3β inhibition was previously shown to preserve umbilical cord blood stem cell activity [13]. However, consistent with the localization of GSK-3β in the nuclei of normal BMMC, we found that the number of apoptotic cells in normal BMMC was not significantly changed in the presence or absence of GSK-3β inhibitors after 48 h of treatment (Figure 4; P > 0.05). The results obtained with GSK-3β inhibition in OSI-906 supplier normal progenitors versus ALL cells provide evidence of a significant therapeutic selectivity. Pharmacologic inhibition of GSK-3β decreased NF-κB-mediated expression of an antiapoptotic molecule in ALL cells Pharmacologic inhibition of GSK-3β induced apoptosis in ALL cells, so we further investigated whether inhibition of GSK-3β affects NF-κB-mediated expression Angiogenesis inhibitor of the antiapoptotic gene survivin in cells from 10 patients with ALL. We found that inhibition of GSK-3β resulted in decreased mRNA and protein expressions of NF-κB target gene survivin in ALL cells relative to control

cells (Figure 5). After completion of these experiments, we summarized the data and represented it as a mean value (Figure 5 legend). SB216763 (10 μM) and LiCl (10 mM) treatment resulted

in a 47.7% and 25% reduction in survivin mRNA levels, respectively. Moreover, the levels of survivin mRNA decreased dose-dependently after treatment with both LiCl and SB216763. These Decitabine order results indicate that the inhibition of GSK-3β does not affect the nuclear accumulation of NF-κB p65 but might alter the ability of NF-κB to regulate target gene promoters in ALL cells. Figure 5 Inhibition of GSK-3β decreased NF-κB-mediated expression of the antiapoptotic molecule survivin in ALL cells. Cells from patients with ALL were treated with controls (NaCl/DMSO) or GSK-3β inhibitors (LiCl/SB216763) for 48 h. (A) The cell pellet was collected and RNA was obtained, then RT-PCR analysis was performed. (B) Survivin mRNA levels were normalized to GAPDH levels in each group. NaCl (48 ± 4)% vs. LiCl (5 mM (40 ± 5)%, 10 mM (36 ± 3)%); DMSO (44 ± 5)% vs. SB216763 (5 μM (38 ± 4)%, 10 μM (23 ± 3)%). (C) Total cell lysates were separated by SDS-PAGE, transferred to PVDF membrane, and immunoblotted with the indicated antibodies. *P < 0.05 vs. controls, **P < 0.01 vs. controls. DNA marker; 1: NaCl; 2: DMSO; 3: LiCl, 5 mM; 4: LiCl, 10 mM; 5: SB216763, 5 μM; 6: SB216763,10 μM. Discussion GSK-3β has recently been shown to be a crucial enzymatic regulator of cancer cell survival in human tumorigenesis [14, 15].

Comments are closed.